Global Influenza Drug Market, By Type (Influenza A, Influenza B, and Influenza C), Treatment (Vaccines and Drugs), Route of Administration (Oral, Intramuscular, Intradermal, Intranasal, and Intravenous), Age (Pediatrics and Adults), End User (Hospitals, and Home Care), Distribution Channel (Direct Tenders and Retail Sales) - Industry Trends and Forecast to 2031.
Influenza Drug Market Analysis and Size
One driving factor for the global influenza drug market is the rising awareness regarding influenza and its potential complications, which is fueling an increased demand for preventive and therapeutic solutions. However, a notable challenge is the presence of generic versions of influenza drugs, leading to price pressures and potentially shrinking profit margins for manufacturers. Despite this, an opportunity exists in the development of novel and more effective drugs to address emerging strains of the influenza virus, providing a competitive advantage. Nevertheless, a persistent challenge is the necessity for ongoing research and development efforts to match the evolving nature of the influenza virus and its tendency to develop resistance to current treatments.
Data Bridge Market Research analyzes that the global influenza drug market is growing with a CAGR of 6.5% in the forecast period of 2024 to 2031 and is expected to reach USD 14.22 billion by 2031 from USD 8.73 billion in 2023. The rising prevalence of various types of cancer is expected to drive the market’s expansion.
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million
|
|
Segments Covered
|
Type (Influenza A, Influenza B, and Influenza C), Treatment (Vaccines, Drugs), Route of Administration (Oral, Intramuscular, Intradermal, Intranasal, and Intravenous), Age (Pediatrics and Adults), End User (Hospitals, and Home Care), Distribution Channel (Direct Tender and Retail Sales)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, Italy, U.K., France, Switzerland, Spain, Russia, Turkey, Belgium, Netherlands, Rest of Europe, China, India, South Korea, Japan, Thailand, Australia, Singapore, Indonesia, Malaysia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, Saudi Arabia, U.A.E., South Africa, Egypt, Israel and Rest of Middle East and Africa
|
|
Market Players Covered
|
GSK plc., Sanofi S.A., CSL, Astrazeneca Plc, F. Hoffmann-La Roche Ltd , Viatris Inc., Abbott, Amneal Pharmaceuticals LLC., AbbVie Inc BioCryst Pharmaceutucals, Inc., Lupin, Zydus Pharmaceuticals, Inc., Macleods Pharmaceuticals Ltd., Viatris Inc., DAIICHI SANKYO COMPANY, LIMITED, Cipla Inc., Shionogi & Co., Ltd. , Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, and NATCO Pharma Limited, and Alvogen, among others
|
Market Definition
Influenza drugs are medications created to either prevent or treat the flu, a contagious respiratory sickness. They include antiviral drugs that focus on the flu virus itself, as well as drugs that help relieve symptoms like fever, cough, and congestion. These medications are essential for handling and lessening the impact of flu outbreaks, particularly during times of widespread transmission or pandemics.
Global Influenza Drug Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail as below:
Drivers
- Increasing Prevalence Rate of Influenza
The global influenza drugs market is experiencing a significant boost in growth due to the increasing prevalence of viral infections worldwide. The prevalence rate of influenza continues to underscore the critical need for advancements in influenza drugs and vaccines. With the emergence of various strains and the constant threat of seasonal outbreaks, the market for influenza medications has witnessed significant growth. Among the key contributors to this expansion are the development and adoption of vaccines with different valency formulations. Quadrivalent vaccines, for instance, offer protection against four different influenza strains, providing broader coverage compared to their trivalent counterparts. These vaccines are available in various forms, including injection and nasal spray, catering to different preferences and needs. The quadrivalent injection offers a convenient and effective method of immunization, particularly for individuals seeking quick and reliable protection against influenza. On the other hand, the nasal spray formulation provides an alternative option, especially for those averse to needles. Additionally, trivalent vaccines remain essential in regions where specific strains are prevalent, ensuring targeted protection against circulating influenza viruses. By incorporating diverse valency options, including quadrivalent and trivalent formulations, the influenza drugs and vaccine market continues to evolve, offering comprehensive solutions to combat the spread of the disease and mitigate its impact on public health.
For instance,
- In October 2023, according to the article published by WHO, seasonal influenza presents a significant global health burden, with approximately a billion cases reported annually, including 3–5 million cases of severe illness. The impact is particularly severe in developing countries, where 99% of deaths in children under 5 years of age with influenza-related lower tract infections and due to which deaths occur in the range from 290,000 to 650,000 annually, highlighting the seriousness of the disease and its potential consequences, especially in vulnerable populations
- In November 2021, according to the article published by NCBI, influenza epidemics pose a significant public health threat, resulting in 290,000–650,000 deaths worldwide each year. However, the toll of influenza pandemics can be even more devastating. The A(H1N1) pandemic of 1918–1919, also known as the Spanish flu, stands as a stark reminder of the potential severity of influenza outbreaks. This pandemic resulted in an estimated 20–50 million deaths globally, making it one of the deadliest pandemics in history
In conclusion, the development and utilization of multi-valent influenza drugs and vaccines, such as quadrivalent formulations and alternative delivery methods like nasal sprays, are crucial steps towards effectively managing the prevalence of influenza. This multi-pronged approach not only enhances vaccination coverage but also contributes significantly to the growth of the influenza drug and vaccine market. Hence, as the global healthcare industry continues to prioritize health, the increasing prevalence of viral infections acts as a catalyst for advancements in treatment modalities, contributing to the sustained growth of the global influenza market.
- Government Initiatives and Vaccination Programs
Increased government initiatives and expanded vaccination programs play a pivotal role in driving growth within the influenza drug market by fostering the stimulating demand. As governments worldwide prioritize public health through comprehensive immunization strategies, pharmaceutical companies specializing in influenza drugs stand to benefit significantly. By actively participating in government initiatives, these companies gain access to lucrative contracts and procurement opportunities for supplying vaccines to national immunization programs. Moreover, engagement in vaccination programs allows pharmaceutical firms to showcase the efficacy and safety of their influenza drugs, enhancing their reputation and market visibility. As governments increasingly prioritize preparedness against seasonal influenza outbreaks and potential pandemics, the demand for innovative vaccines and therapeutics continues to rise. Companies that actively collaborate with government agencies, provide reliable supply chains, and demonstrate commitment to public health objectives are poised to capitalize on this growing market demand. By leveraging government partnerships and actively participating in vaccination programs, pharmaceutical companies can not only contribute to the global fight against influenza but also drive sustainable growth and expansion within the influenza drug market. . Governments also focusing on campaigns, emphasizing the importance of vaccination and adherence to prescribed treatment regimens, further driving the market's growth.
For instance,
- In December 2023, according to the article published by Centers for Disease Control and Prevention, U.S government start National Influenza Vaccination Week (NIVW) which is an annual observance in December to remind everyone 6 months and older that there’s still time to get vaccinated against flu. This annual event, held in December, aims to raise awareness about the importance of influenza vaccination and encourage more people, particularly those in high-risk groups, to get vaccinated. NIVW also provides resources and tools to healthcare providers to facilitate vaccination efforts across the country.
- In July 2023, according to the article published by Department of Health and Aged Care , the Australian government launched the National Immunization Program (NIP) to enhance access to influenza vaccines for eligible populations. The program provides free influenza vaccines to vulnerable groups, including children aged 6 months to less than 5 years, pregnant women, Aboriginal and Torres Strait Islander people, and individuals aged 65 years and older. This initiative aims to reduce the burden of influenza and its associated complications on public health.
- In March 2024, according to the article published by Ministry of Health & Family Welfare, Universal Immunization Program (UIP) (ongoing) launched in 1985, aims to provide vaccination against preventable diseases to all children across the country. In recent years, India has expanded its immunization efforts to include influenza vaccination for high-risk groups, such as healthcare workers, elderly individuals, and those with underlying health conditions. These vaccines, often available in both trivalent and quadrivalent formulations include antiviral which help safeguard against various strains of influenza, including Influenza type B. By incorporating these vaccines into the UIP, India aims to reduce the burden of influenza-related illness and contribute to the overall improvement of public health outcomes across the nation.
In conclusion, the increasing involvement in various government initiatives and vaccination programs significantly contributes to the overall revenue growth of pharmaceutical companies specializing in influenza drugs. By aligning with governmental priorities and actively participating in immunization strategies, these companies gain access to lucrative contracts and procurement opportunities, driving demand for their products. Moreover, engagement in vaccination programs allows pharmaceutical firms to demonstrate the efficacy and safety of their influenza drugs, enhancing their reputation and market visibility, thus attracting more customers globally and expected to act as a driver for market growth
Opportunity
- Integration of Telemedicine and Digital Health Solutions
Telemedicine offers healthcare providers the ability to remotely consult with patients, providing timely assessment and management of influenza symptoms without the need for face-to-face visits. This is particularly beneficial during influenza outbreaks, as it reduces the risk of virus transmission in healthcare settings and improves patient flow management.
Digital health solutions, such as mobile apps and wearable devices, are crucial for monitoring influenza symptoms and ensuring treatment adherence. These tools allow patients to track their symptoms, medication schedules, and overall health status, providing valuable data for remote monitoring by healthcare providers. Additionally, these digital tools empower patients to play a more active role in their healthcare, leading to improved treatment outcomes.
For Instance,
- In April 2022, according to an article published by BioMed Central Ltd, during a telehealth visit for a patient with influenza-like illness, a test threshold of around 25% and a treatment threshold of about 60% has been established. The inclusion of home influenza test outcomes decreased uncertainty and markedly reduced the necessity for in-person visits.
- In February 2022, according to an article published by MDPI, maternal influenza vaccination reduces illness and death in pregnant women and lowers risks for babies. A study on the "Influenza Vaccination Reminder Application" found it improved pregnant women's knowledge, attitudes, and intention to get vaccinated. The app, accessible on smartphones, offers valuable information, promoting vaccination and preventing missed opportunities.
- In September 2021, according to an article published by Johnson & Johnson Services, Inc., Cue Health is a digitally connected health monitoring system that begins with a rapid at-home diagnostic test. This test is linked to a telemedicine provider who can prescribe medication based on the test result. Originally focused on influenza, Cue Health is a rapid point-of-care diagnostics company.
- In October 2020, according to an article published by National Institutes of Health, Oseltamivir can reduce the duration of influenza symptoms, but it must be given within 48 hours of symptom onset. However, in primary care settings, only 20% of patients receive oseltamivir. This low rate is often due to false negative test results and patients seeking treatment after the 48-hour window. Direct-to-consumer (DTC) telemedicine could address these challenges by connecting patients with physicians 24 hours a day. This approach could help overcome delays in treatment and avoid exposing others to infection.
In conclusion, the integration of telemedicine and digital health in influenza diagnosis and treatment enhances healthcare accessibility, improves patient convenience, and enables more personalized and timely care. This integration also creates new opportunities for drug delivery and monitoring, enabling remote monitoring of patients' health status and facilitating the delivery of antiviral medications to remote or underserved areas. Overall, this integration represents a significant opportunity for advancing healthcare delivery in the management of influenza and other infectious diseases.
Restraint/Challenge
- Adverse Effect of Anti-Influenza Drugs
Influenza drugs, despite their efficacy in managing influenza infections, can act as a restraint for market growth due to the potential occurrence of adverse side effects. While common side effects like nausea, vomiting, headache, and diarrhea are generally tolerable, more severe reactions such as allergic responses, skin rash, or respiratory distress can deter patients from continued use. The rare occurrence of neuropsychiatric events, such as hallucinations or abnormal behavior, associated with antiviral medications like oseltamivir (Tamiflu) and zanamivir (Relenza), particularly in younger patients, raises concerns among healthcare providers and patients alike. These adverse effects may lead to hesitancy in prescribing or using influenza drugs, impacting market demand and growth.
For instance,
- In Feb 2020, according to the article published by NCBI, the adverse effects of neuraminidase inhibitors (NAIs) exhibit age-dependent variability, as observed in the findings reported by WebMD. In younger patients administered oseltamivir, a disproportionality in adverse reactions such as vomiting and hallucinations was detected. Conversely, older patients receiving peramivir exhibited adverse events including abnormal hepatic function, cardiac failure, shock, and cardio-arrest. Psychiatric disorders were most prevalent across both younger and older age groups, while gastrointestinal disorders predominated in adults administered oseltamivir
- In April 2024, according to the article published by Mayo Foundation for Medical Education and Research (MFMER), symptom such as nausea, puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue, severe headache, skin rash, stiff neck and/or back, and sudden numbness and weakness in the arms and legs, can be associated with severe adverse reactions to certain drugs and supplements used to treat influenza. While influenza medications like oseltamivir (Tamiflu) and zanamivir (Relenza) are generally well-tolerated, in rare cases, individuals may experience severe allergic reactions or adverse effects.
In conclusion, while influenza drugs are effective in managing influenza infections, the occurrence of adverse side effects acts as a significant restraint on market growth. Common side effects such as nausea, vomiting, and headache, along with more severe reactions like allergic responses and neuropsychiatric events, can deter patients from using these medications. Concerns about safety and tolerability may lead to hesitancy among healthcare providers in prescribing influenza drugs and decrease patient adherence to treatment regimens.
Recent Developments
- In November 2023, AstraZeneca has announced a partnership and investment deal with Cellectis, a clinical-stage biotech company, to speed up the development of new therapies in areas with significant unmet medical needs such as oncology, immunology, and rare diseases. This collaboration will allow AstraZeneca to utilize Cellectis' gene editing technologies and manufacturing capabilities to create innovative cell and gene therapy products, enhancing AstraZeneca's portfolio in this field.
- In June 2023, GSK plc. and BELLUS Health Inc. announced today that GSK has finalized the acquisition of BELLUS, a biopharmaceutical company dedicated to improving the lives of patients with refractory chronic cough (RCC). This acquisition will enhance GSK's portfolio by adding BELLUS's expertise in refractory chronic cough (RCC) treatment, strengthening its position in addressing unmet medical needs in this area.
- In June 2023, Sanofi hosted a Vaccines Investor Event focusing on its pipeline, showcasing how its strategy is backed by vaccines R&D. The company aims for sustained growth in the vaccines business through core franchises in influenza, meningitis, and pediatric vaccines, along with a best-in-class RSV franchise to protect infants, toddlers, and older adults. This event will help Sanofi highlight its strategic focus on vaccines R&D and core franchises, showcasing its potential for sustained growth in the vaccines business.
- In November 2022, CSL has announced that its subsidiary, CSL Seqirus, has signed a collaboration and licensing agreement with Arcturus Therapeutics Holdings Inc to utilize their advanced self-amplifying mRNA (sa-mRNA) vaccine platform technology in the later stages of development. This collaboration will enable CSL Seqirus to leverage Arcturus Therapeutics' advanced sa-mRNA vaccine platform technology, potentially enhancing CSL's vaccine development capabilities.
- In May 2022, GSK plc announced a definitive agreement to acquire Affinivax, Inc., a clinical-stage biopharmaceutical company. The acquisition involves a $2.1 billion upfront payment and up to $1.2 billion in potential development milestones. This acquisition will strengthen GSK's vaccine pipeline by incorporating Affinivax's innovative MAPS technology, enhancing its ability to develop next-generation vaccines for various infectious diseases.
- In January 2022, Natco Pharma Limited has recently announced the signing of a non-exclusive licensing agreement with the Medicines Patent Pool (MPP) in Switzerland. The MPP had previously acquired the license from Merck Sharp & Dohme Corp. (MSD) in the USA for the same purpose. This agreement with the Medicines Patent Pool will enable Natco Pharma Limited to expand its access to important medicines and enhance its ability to provide affordable healthcare solutions to a broader population.
- In January 2022, NATCO Pharma Inc. USA, a wholly owned subsidiary of NATCO Pharma Limited, has finalized the acquisition of Dash Pharmaceuticals LLC, based in New Jersey. Following this transaction, Dash will operate as a 100% wholly owned subsidiary of NATCO Pharma Inc. and a step-down subsidiary of NATCO.
Global Influenza Drug Market Scope
The global Influenza drug market is segmented into six notable segments based on type, treatment, route of administration, age, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the differences in your target markets.
Type
- Influenza A
- Influenza B
- Influenza C
On the basis of type, the market is segmented into Influenza A, Influenza B and Influenza C.
Treatment
- Vaccines
- Drugs
On the basis of treatment, the market is segmented into vaccines and drugs.
Route of Administration
- Oral
- Intramuscular
- Intradermal
- Intranasal
- Intravenous
On the basis of route of administration, the market is segmented into oral, intramuscular, intradermal, intranasal, and intravenous.
Age
- Pediatrics
- Adults
On the basis of age, the market is segmented into pediatrics and adults.
End User
- Hospitals
- Homecare
On the basis of end user, the market is segmented into hospitals and homecare.
Distribution Channel
- Direct Tender
- Retail Sales
On the basis of distribution channel, the market is segmented into direct tenders and retail sales.
Global Influenza Drug Market Regional Analysis/Insights
The global Influenza drug market is analyzed, and market size insights and trends are provided by based on type, treatment, route of administration, age, end user, and distribution channel as referenced above.
The countries covered in this market report are U.S., Canada, Mexico, Germany, France, U.K., Germany, Spain, Italy, France, Russia, Netherlands, Turkey, Switzerland, Belgium, Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Indonesia, Philippines, Malaysia, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel and Rest of Middle East and Africa.
North America is expected to dominate the market due to due to its advanced healthcare infrastructure, well-equipped hospitals, clinics, and home care centers, which ensures quality care for patients.
The U.S. is expected to dominate in the North America market due to its high prevalence of influenza cases, strong healthcare infrastructure, robust pharmaceutical industry, and high public awareness about influenza prevention. U.K. is expected to dominate in the Europe market due to its advanced healthcare system, high vaccination coverage, and proactive government initiatives to combat influenza outbreaks. Japan is expected to dominate in the Asia-Pacific market due to its high healthcare standards, advanced research and development capabilities, and a large elderly population that is particularly vulnerable to influenza.
The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Influenza Drug Market Share Analysis
The global influenza drug market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on the global influenza drug market.
Some of the major players operating in the global influenza drug market are GSK plc., Sanofi S.A., CSL, Astrazeneca Plc, F. Hoffmann-La Roche Ltd , Viatris Inc., Abbott, Amneal Pharmaceuticals LLC., AbbVie Inc BioCryst Pharmaceutucals, Inc., Lupin, Zydus Pharmaceuticals, Inc., Macleods Pharmaceuticals Ltd., Viatris Inc., DAIICHI SANKYO COMPANY, LIMITED, Cipla Inc., Shionogi & Co., Ltd. , Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, and NATCO Pharma Limited, and Alvogen, among others.
SKU-